Theralase Technologies Inc. announced a non-brokered private placement of 4,800,000 units at an issue price of CAD 0.25 per unit for the aggregate gross proceeds of CAD 1,200,000 on June 30, 2023. The transaction included participation from 23 placees including 2 insiders for CAD 1,110,000 and 2 pro groups CAD 180,000. Each Unit consisted of one common share and one common share purchase warrant.

Each Warrant entitles the holder to acquire an additional common share at an exercise price of CAD 0.35 per share for a period of 24 months following the date of issuance. All securities issued under the Offering will be subject to a four month and one day hold period from the closing date under applicable Canadian securities laws, which expires on October 31, 2023. The transaction is subject to receipt of final acceptance from the TSX Venture Exchange.

The Company paid a finder’s fee of CAD 2,700 in cash and issued 5,400 finder’s warrants. Each finder’s warrant is exercisable into one Common Share at an exercise price of CAD 0.35 per share for a period of 24 months after the closing of the Offering.